CytoMed Therapeutics Limited (GDTC)

Biopharmaceutical company focused on developing cell-based therapies.

GDTC Stock Quote

Company Report

CytoMed Therapeutics Limited, a pioneering pre-clinical biopharmaceutical firm headquartered in Singapore, specializes in the advancement of innovative cell-based immunotherapies designed to combat human cancers. At the forefront of its research efforts is CTM-N2D, the company's leading product candidate. CTM-N2D features expanded gamma delta T cells engineered with chimeric antigen receptors targeting natural killer group 2D ligands, aimed at enhancing cytotoxicity against cancerous cells.

In addition to CTM-N2D, CytoMed Therapeutics Limited is actively developing iPSC-gdNKT, utilizing induced pluripotent stem cells (iPSCs) to generate gdNKT cells. These synthetic hybrids combine the characteristics of gamma delta T cells and natural killer (NK) cells, offering a promising approach to broaden the scope of cancer treatment. Another promising candidate in its pipeline is CTM-GDT, which leverages expanded gamma delta T cells equipped with a multi-recognition system to detect and combat various types of cancers.

Since its establishment in 2018, CytoMed Therapeutics Limited has demonstrated a commitment to pushing the boundaries of cancer immunotherapy through innovative research and development. With a focus on leveraging cutting-edge biotechnologies, the company continues to advance its pipeline of therapeutic candidates, aiming to address unmet medical needs and improve outcomes for patients battling cancer worldwide.

GDTC EPS Chart

GDTC Revenue Chart

Stock Research

NKTX ARE DNA NOVT SPH PRT CMCL

GDTC Chart

View interactive chart for GDTC

GDTC Profile

GDTC News

Analyst Ratings